- December 18, 2019
Takeda taps brain-focused Cerevance in quest for new GI targets
Three years after Takeda chipped into Cerevance’s series A, the Big Pharma has come back for more. The duo is inking a research deal focused on identifying new protein targets in the central nervous system to develop new treatments for gastrointestinal disorders. The companies kept details close to the vest but said Cerevance could net more than $170 million in milestones per target.
- December 18, 2019
5 More Private Medtech Companies to Keep Tabs On
Earlier this year, FDA granted a breakthrough device designation for Orchestra BioMed’s Virtue sirolimus-eluting balloon (SEB) in the treatment of below-the-knee peripheral artery disease. The designation came just a few months after the New Hope, PA-based company announced its partnership with Terumo. The agreement included a $30 million up-front payment to Orchestra plus an equity commitment of $5 million.
- December 17, 2019
Immuneering to bolster cancer pipeline, expand services unit with $17M series A
Eleven-year-old Immuneering Corp. has raised its first venture round as it gears up to send its inaugural program to the clinic to treat cachexia in cancer patients and extensively expand its pipeline.
- December 16, 2019
Developing A Smart Inhaler For Optimal Drug Delivery
Historically, inhalation drug delivery was limited to the treatment and management of respiratory diseases, such as asthma or chronic obstructive pulmonary disease. However, this delivery approach has broadened as an alternative treatment option for a number of systemic diseases,[i] including endocrine and neurological diseases, which could benefit from the frequent pulsatile administration afforded by an inhaled delivery option.
- December 11, 2019
Synaptive Medical announces close of $25M preferred share financing to expand global footprint
Synaptive Medical Inc. has completed the first round of a new preferred equity investment totaling $25 million led by Guelph-Ontario-based Linamar Corp., which also entered into a manufacturing agreement with Synaptive, and Calgary’s Audible Capital Corp.
- December 11, 2019
Cleveland company developing technology to help patients with diabetes
As the cost of life-saving insulin soars for people with diabetes, a Cleveland company is developing nanotechnology that could help. The technology, from Diasome, makes insulin more effective in the body so less is needed to regulate blood sugar. Insulin costs for patients with type one diabetes doubled between 2012 and 2016, according to the nonprofit Health Care Cost Institute.
- December 10, 2019
Bucks County medical device firm lands $20M credit deal from Silicon Valley Bank
Bucks County medical device company Orchestra BioMed said Tuesday it has entered into a $20 million credit agreement with Silicon Valley Bank. This deal provides Orchestra BioMed with an initial amount of up to $10 million it can use for development and general corporate expenditures during the next 12 months. The remaining will be available to the company if it hits certain undisclosed product development milestones.
- December 9, 2019
Surprise man battling rare disease helping researchers come up with treatment
A man who lives in Surprise is helping researchers come up with a treatment for a rare disease that he was diagnosed with 20 years ago. Jerry DeVries, now 61, is possibly the oldest living person with Proteus Syndrome.
